NRX PHARMACEUTICALS INC (NRXP)

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The firm is engaged in the development of therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The Company’s program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brains N-methyl-D-aspartate (NMDA) receptor and is being investigated in a Phase III trial under the United States Food and Drug Administrations (FDA) Special Protocol Agreement and Therapy Designation in patients with bipolar depression and suicidal ideation. The firm has also initiated a Phase IIb clinical trial in patients with Sub-Acute Suicidality, a substantially broader indication. Its product, NRX-100, is racemic ketamine, which is a generic anesthetic. The company is engaged in the development of aviptadil acetate (ZYESAMI) for the treatment of respiratory failure in COVID-19.

Company Info

NRX PHARMACEUTICALS INC

1201 Orange Street, Suite 600

Wilmington DELAWARE

P: 14842546134

CEO: Richard Ackerman

Employees: 2

Website: https://www.nrxpharma.com/